Chipscreen Biosciences

Focus: Chipscreen Biosciences is a Shenzhen-based oncology and cell therapy focused biotech founded in 2016, currently advancing a diverse pipeline of 30 programs across multiple cancer indications and metabolic diseases. The company is publicly traded and operates as a clinical-stage to Phase 3 player with significant China-centric development.

Oncology Cell Therapy

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Chipscreen Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Chipscreen Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

10 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

chidamide and azacitidine

AML, Adult

N/A

Clinical Trials (1)

NCT06066905A Study of Chidamide With AZA in MRD Positive AML After Transplant

N/A

Help build intelligence for Chipscreen Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to a geographically diverse pipeline with 3 Phase 3 programs (Chiauranib in pancreatic cancer, Chiglitazar in Type 2 diabetes, Tucidinostat in colorectal cancer) offering near-term regulatory catalysts
Opportunity to work across oncology, cell therapy, and metabolic diseases with multiple shots on goal—20 active trials spanning 11 Phase 1, 7 Phase 2, and 3 Phase 3 programs
Public company status provides stability, equity upside potential, and exposure to Asian biotech innovation outside Western pharma incumbents

Watch Out For

Zero active job postings suggest the company is not actively hiring, raising questions about headcount needs, budget constraints, or organizational maturity
Missing critical data (headcount, revenue, R&D spend, cash position, publications) makes it difficult to assess financial health, research output quality, or career trajectory support
Geographically concentrated in China with no disclosed H1B sponsorship data, limiting international mobility and talent pool diversity

Generated by Claude from Chipscreen Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

treatment T

T2DM (Type 2 Diabetes Mellitus)

N/A

Clinical Trials (1)

NCT07412015Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets

N/A

Chiauranib

Small Cell Lung Cancer

N/A

Clinical Trials (1)

NCT05371899Mass Balance Study of [14C]Chiauranib

N/A

CS23546

Advanced Tumors

PHASE_1

Clinical Trials (1)

NCT06245122A Study of CS23546 in Subjects With Advanced Tumors

Phase 1

NWY001

Advanced Solid Tumor

PHASE_1

Clinical Trials (1)

NCT05979155A Study of NWY001 in Subjects With Advanced Solid Tumors

Phase 1

CS231295

Neoplasms

PHASE_1

Clinical Trials (1)

NCT06902350Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors

Phase 1

Chiauranib

Solid Tumors

PHASE_1

Clinical Trials (1)

NCT02122809Phase I Study of Chiauranib in Patients With Advanced Solid Tumors

Phase 1

Chidamide

Peripheral T-cell Lymphoma

PHASE_1

Clinical Trials (1)

NCT02809573Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients

Phase 1

Chiglitazar

Renal Impairment

PHASE_1

Clinical Trials (3)

NCT05515458Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function

Phase 1

NCT07511010Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets

Phase 1

NCT07519265Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets

N/A

Chiglitazar

Hepatic Impairment

PHASE_1

Clinical Trials (1)

NCT05515445Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function

Phase 1

Chiauranib

Non-Hodgkin's Lymphoma

PHASE_1

Clinical Trials (1)

NCT03074825Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma

Phase 1

CS32582 capsule

Healthy

PHASE_1

Clinical Trials (1)

NCT06224595A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles and Food Effect of CS32582 Capsules

Phase 1

Chiauranib

Small Cell Lung Cancer

PHASE_1

Clinical Trials (1)

NCT03216343Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer

Phase 1

Chiglitazar

T2DM

PHASE_1

Clinical Trials (1)

NCT05681273Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.

Phase 1

CS12192 capsule

Healthy

PHASE_1

Clinical Trials (1)

NCT05922709A Clinical Trial of CS12192 in Healthy Subjects

Phase 1

Chiauranib

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT05346601Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers

Phase 1

AK104 IV infusion；Chiauranib oral

SCLC,Extensive Stage

PHASE_1_2

Clinical Trials (1)

NCT05505825A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer

Phase 1/2

Chidamide

Chronic HIV Infections

PHASE_1_2

Clinical Trials (1)

NCT02513901Chidamide in Combination With Antiretroviral Therapy for Eradication of the Latent HIV-1 Reservoir

Phase 1/2

Chiauranib

Small Cell Lung Cancer

PHASE_1_2

Clinical Trials (1)

NCT05271292Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

Phase 1/2

Chiauranib

Ovarian Cancer

PHASE_1_2

Clinical Trials (1)

NCT03166891Phase Ib Study of Chiauranib in Patients With Ovarian Cancer

Phase 1/2

CS32582 capsule（low dose） or matched placebo

Plaque Psoriasis

PHASE_1_2

Clinical Trials (1)

NCT07129382A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis

Phase 1/2

Chiauranib

Non-hodgkin's Lymphoma

PHASE_1_2

Clinical Trials (1)

NCT03974243Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

Phase 1/2

Chiauranib

Hepatocellular Carcinoma

PHASE_1_2

Clinical Trials (1)

NCT03245190Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma

Phase 1/2

Tucidinostat

Non Small Cell Lung Cancer

PHASE_2

Clinical Trials (1)

NCT05519865A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

Phase 2

Anti-PD-1 Antibody Plus Chidamide and Rituximab

Relapsed or Refractory DLBCL

PHASE_2

Clinical Trials (1)

NCT05115409Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)

Phase 2

Chidamide

Non-small-cell Lung Cancer

PHASE_2

Clinical Trials (1)

NCT01836679Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer

Phase 2

Chiauranib

Soft Tissue Sarcoma

PHASE_2

Clinical Trials (1)

NCT05497843Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

Phase 2

chidamide

Multiple Myeloma

PHASE_2

Clinical Trials (1)

NCT03605056Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM

Phase 2

Venetoclax Combining Chidamide and Azacitidine

Leukemia, Myeloid, Acute

PHASE_2

Clinical Trials (1)

NCT05603884VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Phase 2

Chiauranib

Triple-negative Breast Cancer

PHASE_2

Clinical Trials (1)

NCT05336721A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Phase 2

Chidamide

Non Small Cell Lung Cancer

PHASE_2

Clinical Trials (1)

NCT05068427Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Phase 2

chiauranib

Ovarian Cancer

PHASE_2

Clinical Trials (1)

NCT03901118Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

Phase 2

Chiauranib

Pancreatic Ductal Adenocarcinoma

PHASE_2

Clinical Trials (1)

NCT06492915Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2

Chiglitazar Placebo

MASH - Metabolic Dysfunction-Associated Steatohepatitis

PHASE_2

Clinical Trials (1)

NCT07303803A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus

Phase 2

chiglitazar sodium tablets

NASH

PHASE_2

Clinical Trials (1)

NCT05193916A Phase II Clinical Trial of Chiglitazar for NASH

Phase 2

ART plus Chidamide

Chronic HIV Infections

PHASE_2_3

Clinical Trials (1)

NCT02902185Chidamide in Combination With ART for Reactivation of the Latent HIV-1 Reservoir

Phase 2/3

Chidamide

Breast Cancer

PHASE_3

Clinical Trials (1)

NCT02482753Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Phase 3

chiauranib

Ovarian Cancer

PHASE_3

Clinical Trials (1)

NCT04921527Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

Phase 3

Chiauranib

Metastatic Pancreatic Ductal Adenocarcinoma

PHASE_3

Clinical Trials (1)

NCT07445295Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Phase 3

CHOP

Lymphoma, T-Cell, Peripheral

PHASE_3

Clinical Trials (1)

NCT06947967Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Phase 3

Chiglitazar 32mg

Type 2 Diabetes

PHASE_3

Clinical Trials (1)

NCT04807348Chiglitazar Added to Metformin for Type 2 Diabetes

Phase 3

R-CHOP

Diffuse Large B-cell Lymphoma

PHASE_3

Clinical Trials (1)

NCT04231448Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL

Phase 3

Chiglitazar

Type 2 Diabetes

PHASE_3

Clinical Trials (1)

NCT02173457Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients

Phase 3

Chiauranib

Small Cell Lung Cancer

PHASE_3

Clinical Trials (1)

NCT04830813Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer

Phase 3

Tucidinostat

Colorectal Cancer

PHASE_3

Clinical Trials (1)

NCT06497985A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Phase 3

Chiglitazar

Type 2 Diabetes

PHASE_3

Clinical Trials (1)

NCT02121717Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2016

Portfolio: 48 clinical trials

Top TAs: Oncology, Metabolic Diseases, Infectious Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

28 pipeline

8 pipeline

3 pipeline

1 pipeline

1 pipeline

1 pipeline

Marketed

Pipeline